Diagnostics Platform, Redcliffe Lifetech Raises $61 Million

The leading diagnostic platform, Redcliffe Lifetech is $61 million led by LeapFrog Investments with the participation of Healthquad, Schroders, LC Nueva, Growth Spark Ventures, and existing investors Chiratae Ventures and Alkemi Venture Partners. 

The platform will use the investment to expand its geographical reach across India, with a focus on expanding its low-cost and high-quality D2C diagnostics into tier 2, 3, and 4 cities. The fund will also help to provide affordable, rapid, and convenient pathology services from glucose to genetics in millions of households. 

The funds will also be used to extend Redcliffe's platform and extend its product offerings to radiology, disease data profiling, and lifestyle management. This will also be helpful to shift the focus of Indian healthcare from treatment to early detection and prevention.

Redcliffe said affordable diagnostics help reduce the burden of non-communicable diseases (NCDs) such as heart disease, cancer, and diabetes, which currently cause death to more than 6 million Indians each year.